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SUMMARY
To estimate HCV seroprevalence in subpopulations of women delivering live-born infants in the
North Thames region in England in 2012, an unlinked anonymous (UA) cross-sectional survey of
neonatal dried blood spot samples was conducted. Data were available from 31467 samples from
live-born infants received by the North Thames screening laboratory. Thirty neonatal samples
had HCV antibodies, corresponding to a maternal seroprevalence of 0·095% (95% conﬁdence
interval 0·067–0·136). Estimated HCV seroprevalences in women born in Eastern Europe,
Southern Asia and the UK were 0·366%, 0·162% and 0·019%, respectively. For women born in
Eastern Europe seroprevalence was highest in those aged around 27 years, while in women born
in the UK and Asia-Paciﬁc region, seroprevalence increased signiﬁcantly with age. HCV
seroprevalence in UK-born women whose infant’s father was also UK-born was 0·016%. One of
the 30 HCV-seropositive women was HIV-1 seropositive. Estimated HCV seroprevalence for
women delivering live-born infants in North Thames in 2012 (0·095%) was signiﬁcantly lower
than that reported in an earlier UA survey in 1997–1998 (0·191%). Data indicate that the cohort
of UK-born HCV-seropositive women is ageing and that, in this area of England, most
perinatally HCV-exposed infants were born to women themselves born in Southern Asia or
Eastern Europe.
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INTRODUCTION
Around 185 million people are infected with hepatitis
C virus (HCV) worldwide [1]. Injecting drug use
(IDU) accounts for most new HCV infections in
Europe, while globally, unsafe blood supply and injec-
tions continue to contribute to the transmission of
HCV in regions with the highest prevalence including
Central, East and Southern Asia and North Africa/the
Middle East (prevalence of 3·4–3·8%) [1]. In the UK,
estimates derived from evidence synthesis indicate that
around 214 000 people are chronically infected with
HCV [2], with many remaining undiagnosed (an esti-
mated 40% in London and 48% in Scotland) [3].
HCV-related hospital admissions and deaths from
end-stage liver disease or liver cancer tripled between
1996 and 2010 [3].
The development of direct-acting antivirals (DAAs)
has led to marked advances in treatment for HCV.
Regimens which are shorter, interferon-free and with
high (>95%) pangenotypic efﬁcacy – including for
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cirrhotic and HIV co-infected patients – have raised for
the ﬁrst time the possibility of global targets for HCV
elimination [4]. However, treatment rates in the UK
have historically been low, with only around 3% of
chronically infected individuals treated per year [5].
There are currently no effective interventions to pre-
vent mother-to-child transmission (MTCT) of HCV (al-
though rates may be reduced in HIV co-infected women
with appropriate management) [6, 7] and understanding
of the natural history of vertically acquired HCV dis-
ease is incomplete, particularly in adulthood [8]. In
2011, the UK National Screening Committee upheld
their decision not to recommend routine screening for
HCV in pregnancy, citing the scarcity of population-
based data on contemporary antenatal HCV prevalence
and other key evidence gaps, as well as the lack of ef-
fective interventions to prevent MTCT (http://www.
screening.nhs.uk/hepatitisc-pregnancy); it is currently
recommended that HCV testing is offered to pregnant
women at increased risk of infection only. This recom-
mendation is due to be reviewed in 2015 in light of
updated evidence.
The last unbiased, population-based analysis of
antenatal HCV seroprevalence in the North Thames
region was in women delivering live-born infants be-
tween April 1997 and July 1998 [9]. Substantial demo-
graphic changes have since taken place; the
proportion of live births in England and Wales to
non-UK-born women increased from 16% in 2000 to
26% in 2012 overall, with an increasing number of de-
liveries to women born in Poland, Pakistan and India
[10], and a doubling in the proportion of deliveries to
women aged >35 years in this period [11]. An
improved understanding of HCV epidemiology in
the contemporary antenatal population is needed to
inform screening and management strategies which
reﬂect changing HCV treatment paradigms. The aim
of this study was to establish HCV seroprevalence in
relation to key demographic characteristics in a popu-
lation of women delivering in North Thames in 2012.
METHODS
Data collection
The specimens analysed were collected as part of the
unlinked anonymous (UA) survey of HIV infection in
pregnant women, which was carried out using residual
neonatal dried blood spot (DBS) samples routinely col-
lected for metabolic newborn screening, usually at
around age 1 week. Tests for HCV antibodies were
conducted following testing for HIV-1 antibodies in
the second quarter of 2012 (1 April–30 June) in the
North Thames neonatal screening laboratory. The
North Thames region comprises North London plus
Bedfordshire, Hertfordshire and Essex, and accounted
for about 17% of live births in England and Wales in
2012 [11]. The presence of HCV antibodies in the new-
born infant reﬂects maternal infection status due to
passive transfer of maternal antibodies in utero.
Linking demographic data with neonatal DBS samples
The methods used by the UA survey on HIV in preg-
nant women, including anonymization and record-
matching algorithms and procedures protecting
against deductive disclosure, have been described in
detail elsewhere [12]. All neonatal laboratory records
corresponding to incoming neonatal screening cards
received by the North Thames screening laboratory
were downloaded into an extract ﬁle containing a
unique laboratory number, child’s date of birth and
address. If the mother refuses all routine screening
tests and/or anonymous testing, a blank spot is
punched from the screening card. Fewer than 0·01%
of mothers declined to have these tests performed
for their infants. The laboratory number of the
sample, and the plate and well position are stored in
a ﬁle. This ﬁle was sent to the Centre for Infections,
Public Health England (PHE) for further processing.
After deletion of records from multiple births and
repeat samples required for metabolic testing this ﬁle
was matched to birth registration records at the
Ofﬁce for National Statistics (ONS) which provided
information including hospital of birth, maternal bor-
ough of residence, and parental countries of birth. All
patient-identifying information apart from laboratory
number was then irreversibly deleted by the ONS be-
fore being returned to PHE. This demographic ﬁle
was merged with the laboratory ﬁle using the unique
laboratory number, which was subsequently deleted
from the merged ﬁle before the samples were tested
for HIV-1 and HCV antibodies. Serology results
were merged with the demographic data using plate
identiﬁers and well positions. At the end of the data-
processing cycle all original data ﬁles were irreversibly
deleted.
Laboratory methods
DBS were eluted in PBS Tween-80 overnight at 4 °C
and tested using the HCV Serodia particle agglutination
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test (Fujirebio Inc., Japan), which employs gelatin par-
ticles coated with HCV antigens and can detect HCV
genotypes 1–4. This class of assays has previously
been validated for detection of HCV antibodies in
DBS achieving >95% sensitivity and speciﬁcity [13]. In
our own validation using 16 HCV-antibody-positive
DBS samples from asymptomatic, untreated adults,
and 106 HCV-negative DBS samples from UK blood
donors, 15 of the 16 HCV-positive samples were react-
ive, and all HCV-negative samples were non-reactive,
yielding 94·1% sensitivity and 100% speciﬁcity. All posi-
tive results were repeated and tested with unsensitized
particles to rule out non-speciﬁc reactions.
Explanatory variables
We examined the association between estimated HCV
seroprevalence and the following demographic risk
factors: parental world regions of birth, maternal bor-
ough of residence, and maternal age. The United
Nations classiﬁcation of countries was used to cat-
egorize parental country of birth according to world
geographical regions [14]; however, it should be
noted that the Baltic states (Estonia, Latvia,
Lithuania) were included in Eastern (not Northern)
Europe, because of the epidemiological similarities be-
tween these and other former Soviet Union countries,
with regards IDU-related risk factors for transmission
of blood-borne viruses [15].
Statistical analysis
Data were managed, and analyses were conducted
using the R environment for statistical computing ver-
sion 3.0.1 (CRAN, Austria). Fisher’s exact tests were
used for 2 × 2 comparisons. A logistic regression
model with 2 D.F. spline terms on age as a continuous
variable interacting with maternal region of birth was
ﬁtted.
Ethical approval
Research ethical approval was granted by the East
Midlands Research Ethics Committee (reference 12/
EM/0488).
RESULTS
Results from 31 467 non-repeat DBS specimens were
analysed. Data linkage between birth registration
records from the neonatal screening laboratory for
North Thames and the ONS birth registration records
was achieved for 31 316 (99·5%) DBS samples; for the
151 unlinked records, parental countries of birth were
categorized as missing. There were 2299 (7·3%) infants
born in the North Thames area whose mothers’ bor-
ough of residence was outside the survey area, al-
though it is likely they lived close to it.
Thirty samples were HCV antibody positive
[0·095%, 95% conﬁdence interval (CI) 0·067–0·136],
with seroprevalence varying by maternal region of
birth (Table 1). HCV seroprevalence was low in
UK-born women (0·019%) and highest in women
born in Eastern Europe (0·366%) and the Asia-
Paciﬁc region (0·171%). Of the 26 HCV-seropositive
women whose country of birth was known, three
were born in the UK; the 11 women originating
from Eastern Europe were born in Ukraine, Russia,
Poland, Lithuania, the Czech Republic and
Hungary, with the one woman from Southern
Europe born in Italy. Of the six women originating
from Southern Asia, four were born in Pakistan and
two in India. One woman, born in Eastern Europe,
had HIV co-infection, giving a prevalence of HIV/
HCV co-infection in the population overall of
0·0032% (95% CI 0·0002–0·018).
Table 2 shows anti-HCV prevalence stratiﬁed by
maternal age in neonates of women born in the UK,
Eastern Europe, and the Asia-Paciﬁc region.
Seroprevalence was highest in Eastern European
women aged 26–30 years (0·852%). There was a sign-
iﬁcant difference in age-adjusted seroprevalence be-
tween women born in the UK and in Eastern
Europe (P < 0·001), and also between women born
in the UK and the Asia-Paciﬁc region (P = 0·044). A
logistic regression model ﬁtted with a 2 D.F. spline
term in continuous maternal age showed a signiﬁcant
interaction (P= 0·033) between maternal age and region
of birth, indicating a peak seroprevalence for women
born in Eastern Europe and delivering in 2012 at
around age 27 years, in contrast to a higher seropreva-
lence with increasing age in women born in the UK or
the Asia-Paciﬁc region (Fig. 1). Median maternal age in
the HCV-seropositive women from Eastern Europe was
24 years (range 24–35), compared with 37 years in the
UK/Southern Europe (range 33–41).
Seroprevalence was similar in outer (0·13%) and
inner (0·10%) London (Table 3). Seroprevalence in
metropolitan areas (inner and outer London) was al-
most twice that in non-metropolitan areas (0·116%
and 0·053%, respectively), although this difference
was not statistically signiﬁcant (P = 0·15). Paternal
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region of birth was known for 22 of the 30 infants with
seropositive samples and of these, nine (40·9%) fathers
were born in the UK; however, for only two (9·1%) of
the perinatally exposed infants were both parents
UK-born. HCV seroprevalence in UK-born women
whose infant’s father was also UK-born was low,
0·016% (2/12 511).
DISCUSSION
In this survey maternal HCV seroprevalence was
0·095% overall, with important differences between
subpopulations. Our UA survey design of residual
neonatal DBS is a robust method for reaching un-
biased estimates of infection prevalence in pregnant
women [9, 12], with a pan-genotypic assay which we
validated for use with DBS. The very low proportion
of mothers declining metabolic or further tests per-
formed on their infants’ DBS ensures that refusal is
not a source of bias. Prior to this study the last ante-
natal HCV seroprevalence data from England came
from another UA survey carried out in 1997–1998 in
the same region with similar methodology [9]. The
overall seroprevalence obtained here is signiﬁcantly
lower (P < 0·001) than the 0·191% reported 15 years
earlier (based on the seroprevalence estimates
obtained with only the conﬁrmed cases) [9]. HCV
seroprevalence in UK-born women delivering in
North Thames has declined signiﬁcantly over the
past 15 years, from 0·13% (95% CI 0·10–0·16) to
0·02% (95% CI 0·004–0·060). For UK-born women
whose age was known, the age-adjusted seropreva-
lences between the two studies also differed signiﬁ-
cantly (P = 0·003), with these uniformly higher in
women giving birth in 1997–1998. The antenatal
HCV antibody prevalence in UK-born women in
our study is just within the 95% credible interval
(CrI) for women aged 15–59 years who have never
injected drugs and are of white or other (non-South
Asian) ethnicity living in England in a recent evidence
synthesis analysis (seroprevalence 0·04%, 95% CrI
0·02–0·07) [3].
Seroprevalence in women born in the Asia-Paciﬁc
region showed a slight decline since the earlier study,
from 0·22% to 0·17%, but this area of origin remained
important with respect to higher HCV seroprevalence,
consistent with the epidemiology of HCV in the UK
[16, 17] and globally [1, 18]. Women born in
Table 1. Neonatal anti-HCV prevalence by maternal region of birth, North Thames, England, 2012
Maternal region of birth HepC− HepC+ % total samples Prevalence (%)
Africa 3188 1 10·14 0·031
Northern Africa 304 0 0·97 0·000
Western Africa 1154 0 3·67 0·000
Central Africa 252 1 0·80 0·395
Eastern Africa 1258 0 4·00 0·000
Southern Africa 220 0 0·70 0·000
UK 15 563 3 49·51 0·019
Rest of Europe 4480 12 14·29 0·267
Northern Europe 332 0 1·06 0·000
Western Europe 526 0 1·67 0·000
Eastern Europe 2997 11 9·57 0·366
Southern Europe 625 1 1·99 0·160
Americas 835 0 2·66 0·000
North America 286 0 0·91 0·000
Central America & Caribbean 275 0 0·87 0·000
South America 274 0 0·87 0·000
Asia-Paciﬁc 5843 10 18·62 0·171
Western Asia 747 0 2·38 0·000
Central Asia 457 1 1·46 0·218
Southern Asia 3691 6 11·76 0·162
South Eastern Asia 388 1 1·24 0·257
Eastern Asia 327 1 1·04 0·305
Oceania 233 1 0·74 0·427
Not known 1528 4 4·87 0·261
Total 31 437 30 100·00 0·095
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Southern Europe had around a tenfold lower HCV
seroprevalence compared to their counterparts in the
late 1990s, from 1·58% to 0·16%, while seroprevalence
in women born in Eastern Europe remained relatively
stable (0·366% here vs. 0·40% in 1997–1998) [9]. By
2012, HCV seroprevalence in Eastern European-
born women was 18 times higher than that in
UK-born women. Consistent with national data, the
overall proportion of births to UK-born women
declined considerably between the 1997–1998 study
(72%) and our study (50%) [9]; another noteworthy
trend was the 19-fold increase in the proportion of de-
liveries to women born in Eastern Europe (from 0·5%
to 19·2%). Trends in HCV seroprevalence in subpopu-
lations and the shifting socio-demographic proﬁle of
pregnant women with HCV thus need consideration
in the context of the changing patterns of births over-
all in the UK.
People who inject drugs (PWID) are important to
consider when interpreting the epidemiology of HCV.
An estimated 80–85% of individuals with chronic
HCV infection in England are PWID [3, 19], with
Table 2. Neonatal anti-HCV prevalence by maternal age: mothers born in the UK, Eastern Europe and Asia-Paciﬁc
and delivering in North Thames, England, 2012
Maternal region of birth
Maternal age
(years)
UK Eastern Europe Asia-Paciﬁc
HCV− HCV+ Prev. (%) HCV− HCV+ Prev. (%) HCV− HCV+ Prev. (%)
<21 827 0 0·000 96 0 0·000 75 0 0·000
21–25 2180 0 0·000 461 1 0·217 835 0 0·000
26–30 3560 0 0·000 939 8 0·852 1634 2 0·122
31–35 3226 1 0·031 609 1 0·164 1245 2 0·161
>35 2945 2 0·068 350 1 0·286 1013 5 0·494
Total* 12 738 3 0·024 2455 11 0·448 4802 9 0·187
* Only women with known date of birth are included in this table.
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Fig. 1. Estimated HCV seroprevalence by maternal age and region of birth, North Thames, England.
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HCV prevalence of around 45% in current users, 30%
in those with past use [3] and 18% in recent initiates
[20]. The size of the population of PWID and
ex-PWID is difﬁcult to estimate reliably [21], particu-
larly in pregnant women because of the perceived or
real stigma associated with drug use [22]. Prevalence
of current IDU was recently estimated as 0·65% in
England and 0·79% in London, with around 3/1000
women estimated to be PWID [3]. A history of inject-
ing drugs is more common in women originating
from Central and Eastern Europe, with a survey of
migrants living in London reporting that 2·5% of
women were PWID [23], reﬂecting higher rates
of IDU in Eastern vs. Western Europe [24]. HCV sero-
positivity rates in PWID are higher in Central and
Eastern Europe than in the UK, with estimates of
up to 85–94% in Lithuania, 66–83% in Romania,
61–73% in Ukraine and 49–96% in Russia [25, 26].
Data on HCV prevalence in contemporary preg-
nant women in Europe are scarce. In a large study
in The Netherlands in 2003 in which around 4500 ran-
domly selected samples from routine antenatal bloods
were screened (half from women of non-Dutch ori-
gin), anti-HCV prevalence was 0·33% (95% CI 0·20–
0·54), and lower in women of Western ethnicity
(0·1%, 95% CI 0·04–0·34) than in those of
non-Western ethnicity (0·6%, 95% CI 0·34–1·04)
[27], as found here. In Ukraine, results from antenatal
HCV screening in around 168 000 women in 2010
indicated a seroprevalence of 2·27% overall (Dr
R. Malyuta, personal communication, June 2013),
while a Russian study reported an antenatal HCV
prevalence of 3% [28]. HCV seroprevalence was ten-
fold lower than this in women from Eastern Europe
here, possibly reﬂecting the ‘healthy migrant effect’.
In addition to a higher prevalence of IDU, risk factors
for HCV acquisition in women born in Eastern
Europe may include iatrogenic exposures and inad-
equately screened blood products.
Our ﬁnding of a low HIV co-infection rate concurs
with the 1997–1998 study in which 2% of
HCV-seropositive women had HIV co-infection [9].
Data from the UK indicate low rates of HCV
co-infection in women living with HIV, with 1·9% of
pregnant women in 2008–2010 and 4·6% of women re-
ceiving HIV care in 2000–2011 being anti-HCV posi-
tive [29] (S. Huntington, personal communication,
March 2014). This reﬂects the very small proportion
of pregnant women with HIV in the UK being
PWID (e.g. 1·5% in 2007–2011) [30].
Population-based studies have demonstrated a birth
cohort effect for HCV prevalence [1], e.g. with the
‘baby boomers’ born during 1945–1965 in the
United States having a disproportionately high sero-
prevalence (3·25%), reﬂecting the peak in HCV inci-
dence in the 1980s [31]. Here, there were no HCV
infections in UK-born women aged <31 years, and
those aged 31–35 years (born 1977–1981) had a sero-
prevalence of 0·031%, similar to the 0·02% seropreva-
lence in women aged <21 years in the 1997–1998
study born in the same period [9]. While seropreva-
lence increased with age in women born in the UK
and Asia-Paciﬁc, the peak seroprevalence in Eastern
European women delivering in 2012 was at around
27 years.
In UK-born children, MTCT is the major mode of
acquisition of HCV infection. Our ﬁndings suggest
that there may be 120 infants born to HCV-positive
mothers in North Thames annually. As the proportion
of deliveries to women born outside of the UK is sub-
stantially higher in North Thames compared to
England overall, further work is required to generalize
these ﬁndings. To model the number of new vertical
HCV infections occurring nationally, we therefore
plan to estimate population-level antenatal HCV
prevalence for England, based on the age- and
region-of-origin-speciﬁc seroprevalence data obtained
here. Our results may also inform estimates of HCV
seroprevalence in women of child-bearing age in
North Thames, which would need to account for dif-
ferent fertility rates in subpopulations at varying risk
of HCV, e.g. PWID and migrants from countries
with high HCV seroprevalence [32].
The HCV treatment pipeline is impressive and the
development of short, all oral and highly efﬁcacious
regimens has changed the HCV treatment paradigm,
although the pricing of currently licensed drugs is
Table 3. Neonatal anti-HCV prevalence by maternal
borough of residence, North Thames, England, 2012
Borough HepC− HepC+
% total of
samples
Prev.
(%)
Inner London 8287 8 26·39 0·10
Outer London 11 486 15 36·58 0·13
Non-metropolitan 9367 5 29·81 0·05
Outside survey
area*
2297 2 7·31 0·09
Total 31 437 30 0·10
* Considered with the North Thames population throughout
our analyses.
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very high [33]. Although there is the potential to cure
the majority of those treated, access to treatment is
not universal and has become a topic of considerable
global debate [34]. DAAs have yet to be licensed for
paediatric treatment and their potential application
in pregnancy (for maternal treatment and prevention
of MTCT) has yet to be evaluated. The public health
impact of preventing vertical transmissions through
treatment of women with HCV prior to or potentially
during pregnancy, curing HCV infection in early
childhood, and of averting HCV-related sequelae in
the women themselves is likely to be considerable.
Our study has some limitations. In around 0·05%
of cases, linkage with birth registration data was
not possible, because the baby was not registered or
due to failure of the linkage process, resulting in
some missing data. Although UA methodology
reduced bias, the outcome was HCV seropositivity
in the neonate (and thus in the mother), which does
not equate to maternal chronic HCV infection
given the potential for spontaneous viral clearance
and HCV treatment. This approach was limited to
women delivering live-born babies, and also pre-
cluded investigation of factors such as genotype, ma-
ternal disease status, infant outcomes and whether or
not the women were aware of their HCV status. For
7% of the neonates sampled, the mother was resident
outside of the North Thames area and although
HCV seroprevalence was similar in this group to
women living in North Thames, we were unable to
characterize these women’s borough of residence.
The sensitivity and speciﬁcity to detect HCV sero-
prevalence from DBS samples found in our own val-
idation and several other studies is high, and
differences between our results and those of the
1997–1998 study on neonatal DBS in North
Thames are commensurate with substantial demo-
graphic changes occurring in the intervening years.
An understanding of population-based anti-HCV
prevalence is important for public health surveillance,
determining screening policies and forecasting treat-
ment need. This study provides contemporary ante-
natal HCV seroprevalence data and is the ﬁrst
population-wide study of HCV seroprevalence in
women delivering live-born infants in England for
over 15 years. Our results provide key data on ante-
natal HCV prevalence for consideration in the forth-
coming re-assessment of the UK antenatal HCV
screening policy, as well as providing updated esti-
mates for inclusion in future evidence synthesis mod-
els for the UK as a whole.
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